Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa ...

People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while ...

predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II trials found. At 12 weeks of follow-up, adults with ...

It is intravenously administered, allowing for flexible dosing to reach ideal efficacy Despite AbbVie’s Humira being the only approved biologic in moderate-to-severe hidradenitis suppurativa (HS ...

A new white paper from the market research firm charts the impact of the introduction of biologics as a treatment for HS. First to earn FDA approval in the space was AbbVie’s Humira in 2015 ...

Serum C-reactive protein is being investigated as a biomarker to predict adalimumab response in hidradenitis suppurativa patients. Elevated baseline C-reactive protein levels correlate with a ...

It is intravenously administered, allowing for flexible dosing to reach ideal efficacy Despite AbbVie’s Humira being the only approved biologic in moderate-to-severe hidradenitis suppurativa (HS ...

The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed.

The MIRA trial revealed sonelokimab significantly improved HS patients' conditions. However, additional studies and comparisons with Humira, the current leading treatment, are necessary.